Loading...
Lobe Sciences Ltd.
LOBE.CN•CNQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.03
$0.00(0.00%)
Lobe Sciences Ltd. (LOBE.CN) Stock Overview
Explore Lobe Sciences Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
-83.80%
↓ 83.80%
Profit Growth
$-0.03
↑ 6.09%
EPS Growth
$-0.03
↑ 19.73%
Operating Margin
0.00%
↑ 37.009%
ROE
166.66%
↑ 6.09%
Dividend Yield
0.00%
Analyst Recommendations data is not available for LOBE.CNAnalyst Recommendations details for LOBE.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
CEO
Dr. Frederick Dominick Sancilio M.S., Ph.D.
Headquarters
1199 West Hastings Street, Vancouver, BC
Founded
2012